Reversal of liver fibrosis

Saudi Journal of Gastroenterology

Volumn 15, Issue 1, 2009, Pages 72-79

  Ismail, Mona ^a   Pinzani, Massimo ^b  

^a IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY   (Saudi Arabia)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Antifibrotic; Cirrhosis; Fibrogenesis; Liver fibrosis

Indexed keywords

ALPHA TOCOPHEROL; ANTIFIBROTIC AGENT; ANTIOXIDANT; DELTA INTERFERON; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; FLAVANOID; INTERFERON; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; QUERCETIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

BILE DUCT DISEASE; CELL ACTIVATION; CELL INTERACTION; DISEASE COURSE; EPITHELIUM CELL; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MESENCHYME CELL; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; STELLATE CELL; WOUND HEALING;

EID: 58849106702     PISSN: 13193767     EISSN: 19984049     Source Type: Journal    
DOI: 10.4103/1319-3767.45072     Document Type: Review

References (97)

1. Alcolado R, Arthur MJP, Iredale JP. Pathogenesis of liver fibrosis. Clin Sci 1997;92:103-12.
2. Friedman SL, Roll FJ, Boyles J, Bisslell DM. Hepatic lipocytes: The principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci 1985;82:8681-5.
3. Fallowfield JA, Kendall TJ, Iredale JP, Reversal of fibrosis: No longer a pipe dream? Clin Liver Dis 2006;10:481-97.
4. Schuppan D. Structure of the extracellular matrix in normal and fibrotic liver: Collagens and glycoproteins. Semin Liver Dis 1990;10:1-10.
5. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000;275:2247-50.
6. Friedman SL. Liver fibrosis-from bench to bedside. J Hepatol 2003;38:S38-53.
7. Bataller R, North KE, Brenner DA, Genetic polymorphisms and the progression of liver fibrosis: A critical appraisal. Hepatology 2003;37:493-503.
8. Wanless IR. Pathogenesis of cirrhosis. J Gastroenterol Hepatol 2004;19:S369-71.
9. Anthony PP, Ishak KG, Nayak NC, Poulsen HE, Scheuer PJ, Sobin LH. The morphology of cirrhosis: Working group sponsored by the World Health Organization. J Clin Pathol 1978;31:395-414.
10. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002;36:S74-83.
11. Pinzani M, Rombouts K. Liver fibrosis-from the bench to clinical targets. Dig Liver Dis 2004;36:231-42.
12. Bertolani C, Marra F. The role of adipokines in liver fibrosis. Pathophysiology 2008;15:91-101.
13. Medina J, Arroyo AG, Sanchez-Madrid F, Moreno-Otero R. Angiogenesis in chronic inflammatory liver disease. Hepatology 2004;39:1185-95.
14. Novo E, Cannito S, Zamara E, Valfrè di Bonzo L, Caligiuri A, Cravanzola C, et al. Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells. Am J Pathol 2007;170:1942-53.
15. Pinzani M, Marra F. Cytokine receptors and signalling in hepatic stellate cells. Sem Liv Dis 2001;21:397-416.
16. Rosmorduc O, Wendum D, Corpechot C, Galy B, Sebbagh N, Raleigh J et al. Hepatocellular hypoxia-induced vascular endothelial growth factor expression and angiogenesis in experimental biliary fibrosis. Am J Pathol 1999;155:1065-73
17. Corpechot C, Barbu V, Wendum D, Kinnman N, Rey C, Poupon R, et al. Hypoxia - induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology 2002;35:1010-21.
18. Tugues S, Fernandez-Varo G, Muñoz-Luque J, Ros J, Arroyo V, Rodes J, et al. Antiangiogenic treatment with Sunitinib ameliorated inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 2007;46:1919-26.
19. Parola M, Robino G. Oxidative stress-related molecules and liver fibrosis. J Hepatol 2001;35:297-306.
20. Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 2006;131:934-45.
21. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:109-18.
22. Zamara E, Novo E, Marra F, Gentilini A, Romanelli RG, Caligiuri A, et al. Hydroxynonenal as a selective pro-fibrogenic stimulus for activated human hepatic stellate cells. J Hepatol 2004;40:60-8.
23. De Minicis S, Bataller R, Brenner DA. NADPH oxidase in the liver: Defensive, offensive, or fibrogenic? Gastroenterology 2006;131:272-5.
24. Albano E. Alcohol, oxidative stress and free radical damage. Proc Nutr Soc 2006;65:278-90.
25. Desmet VJ, Roskams T. Cirrhosis reversal: A duel between dogma and myth. J Hepatol 2004;40:860-7.
26. Pinzani M, Rombouts K. Liver fibrosis-from the bench to clinical targets. Dig Liver Dis 2004;36:231-42.
27. Robertson H, Kirby JA, Yip WW, Jones DEJ, Burt AD. Biliary epithelial-mesenchymal transition in post transplantation recurrence of primary biliary cirrhosis. Hepatology 2007;45:977-81.
28. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001;344: 495-500.
29. Campbell MS, Reddy KR. Review article: The evolving role of liver biopsy. Aliment Pharmacol Ther 2004;20:249-59.
30. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
31. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 1994;19:1513-20.
32. Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: The Knodell histology activity index and beyond. Hepatology 2000;31:241-6.
33. Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology 2002;36:S152-60.
34. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449-57.
35. Regev A, Berho M, Jeffers LT, Milikowski C, Molina EG, Pyrsopoulos T, et al. Sampling error and intraobserver variability in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;15:945-51.
36. Afdhal NH. Diagnosing fibrosis in hepatitis C: Is the pendulum swinging from biopsy to blood tests? Hepatology 2003;37:972-4.
37. Kotlyar D, Blonski W, Rustgi V. Noninvasive monitoring of hepatitis C fibrosis progression. Clin Liver Dis 2008;12:557-71.
38. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study. Lancet 2001;357:1069-75.
39. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatits C. Hepatology 2003;38:518-26.
40. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002;36:986-92.
41. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, et al. Serum markers detect the presence of liver fibrosis: A cohort study. Gastroenterology 2004;127:1704-13.
42. Patel K, Gordon SC, Jacobson I, Hézode C, Oh E, Smith KM, et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004;41:935-42.
43. Parkes J, Neil Guha I, Roderick P, Rosenberg W. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol 2006;44:462-74.
44. Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: Longitudinal validation in a randomized trial. J Viral Hepat 2002;9:128-33.
45. Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 2003;38:481-92.
46. Sporea I, Popescu A, Sirli R. Why, who and how should perform liver biopsy in chronic liver diseases. World J Gastroenterol 2008;14:3396-402.
47. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005;41:48-54.
48. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al. Transient elastography: A new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003;29:1705-13.
49. Shaheen A, Wan A, Myers RP. Fibro-test and FibroScan for the prediction of hepatitis C-related fibrosis: A systematic review of diagnostic test accuracy. Am J Gastroenterol 2007;102:2589-600.
50. Popper H, Udenfriend S. Hepatic fibrosis: Correlation of biologic and morphologic investigations. Am J Med 1970;49:707-21.
51. Perez-Tamayo R. Cirrhosis of the liver: A reversible disease? Pathol Ann 1979;14:183-213.
52. Dufour JF, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 1997;127:981-5.
53. Hammel P, Couvelard A, O'Toole D, Ratouis A, Sauvanet A, Flejou JF, et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med 2001;344:418-23.
54. Muretto P, Angelucci E, Lucarelli G. Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation. Ann Intern Med 2002;136:667-72.
55. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004;39:1647-54.
56. Kral JG, Thung SN, Biron S, Hould FS, Lebel S, Marceau S, et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 2004;135:48-58.
57. Kweon YO, Goodman ZD, Dienstag JL, Schiff ER, Brown NA, Burkhardt E, et al. Decreasing fibrogenesis: An immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol 2001;35:749-55.
58. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-32.
59. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histological improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517-24.
60. Kweon YO, Goodman ZD, Dienstag JL, Shiff ER, Brown NA, Burkardt E, et al. Decreasing fibrogenesis: An immunoistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol 2001;35:749-55.
61. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003;124:105-17.
62. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-13.
63. Farci P, Roskams T, Chessa L, Peddis G, Mazzoleni AP, Scioscia R, et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: Regression of advanced hepatic fibrosis. Gastroenterology 2004;126:1740-9.
64. Serpaggi J, Carnot F, Nalpas B, Canioni D, Guéchot J, Lebray P, et al. Direct and indirect evidence for the reversibility of cirrhosis. Hum Pathol 2006;37:1519-26.
65. Hui CK, Leung N, Shek TW, Yao H, Lee WK, Lai JY, et al. Hong Kong Liver Fibrosis Study. Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients. Hepatology 2007;46:690-8.
66. Wakim-Fleming J, Mullen KD. Long-term management of alcoholic liver disease. Clin Liver Dis 2005;9:135-49.
67. Kral JG, Thung SN, Biron S, Hould FS, Lebel S, Marceau S, et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 2004;135:48-58.
68. Desmet VJ, Roskams T. Reversal of cirrhosis: Evidence based medicine? Gastroenterology 2003;125:629-30.
69. Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis: Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med 2000;124:1599-607.
70. Desmet VJ. Milestones in liver disease: Scoring chronic hepatitis. J Hepatol 2003;38:382-6.
71. Popper H. What are the major types of hepatic cirrhosis? In: Ingelfinger F, Relman A, Finland M, editors. Controversies in internal medicine. Philadelphia, PA: WB Saunders; 1966. p. 233-43.
72. Fauerholdt L, Schlichting P, Christensen E, Poulsen H, Tygstrup N, Juhl E. The Copenhagen study group for liver disease: Conversion of micronodular into macronodular cirrhosis. Hepatology 1983;3: 928-31.
73. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. United network for organ sharing liver disease severity score committee: Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91-6.
74. Seef LB, Lie BA. Is cirrhosis an inevitable consequence of chronic hepatitis C infection? Clin Gastroenterol Hepatol 2005;3:840-2.
75. Angulo P. Non alcoholic fatty liver disease. N Engl J Med 2002;346:1221-31.
76. Goodman ZD, Becker RL, Pockros PJ, Afdhal NH. Progression of fibrosis in advanced chronic hepatitis C: Evaluation by morphometric image analysis. Hepatology 2007;45:886-94.
77. Bosch J, Garcia-Pagan JC, Berzigotti A, Abraldes Jl. Measurement of portal pressure and its role in the management of chronic liver disease: Prognosis in Patients with Cirrhosis. Sem Liver Dis 2006;26:348-62.
78. Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985;5:419-24.
79. Pinzani M, Vizzutti M, Arena U, Marra F. Technology insight: Noninvasive assessment of liver fibrosis by biochemical scores and elastography. Nat Clin Pract Gastroenterol Hepatol 2008;5:95-106.
80. Fontana RJ, Goodman ZD, Dienstag J, Bonkowsky HL, Naishadham D, Sterling RK, et al. Relationship of serum markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 2008;47:789-98.
81. Vizzutti F, Arena U, Romanelli RG, Rega L, Foschi M, Colagrande S, et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology 2007;45:1290-7.
82. Friedman SL. The cellular basis of hepatic fibrosis: Mechanisms and treatment strategies. N Engl J Med 1993;328:1828-35.
83. Rockey DC. New Therapies in hepatitis C virus and chronic liver disease: Antifibrotics. Clin Liver Dis 2006;10:881-900.
84. Dufour JF, DeLellis R, Kaplan MM. Regression of hepatic fibrosis in hepatitis C with long term interferon treatment. Dig Dis Sci 1998;43:2573.
85. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16.
86. Pinzani M, Rombouts K. Liver fibrosis: From the bench to clinical targets. Dig Liver Dis 2004;36:231-42.
87. Friedman SL, Maher JJ, Bissell DM. Mechanisms and therapy of hepatic fibrosis: Report of the AASLD single topic basic research conference. Hepatology 2000;32:1403-8.
88. Houglum K, Venkataramani A, Lyche K, Chojkier M. A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology 1997;113:1069-73.
89. Parola M, Leonarduzzi G, Biasi F, Albano E, Biocca ME, Poli G, et al. Vitamin E dietary supplementation protects against carbon tetrachloride-induced chronic liver damage and cirrhosis. Hepatology 1992;16:1014-21.
90. Rockey DC, Chung JJ. Interferon gamma inhibits lipocyte activation and extracellular matrix mRNA expression during experimental liver injury: Implications for treatment of hepatic fibrosis. J Investig Med 1994;42:660-70.
91. Pavanato A, Tunon MJ, Sanchez-Campos S, Marroni CA, Llesuy S, Gonzalez-Gallego J, et al. Effects of quercetin on liver damage in rats with carbon tetrachloride-induced cirrhosis. Dig Dis Sci 2003;48:824-9.
92. Croquet V, Moal F, Veal N, Wang J, Oberti F, Roux J, et al. Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension. J Hepatol 2002;37:773-80.
93. Warner FJ, Lubel JS, McCaughan GW, Angus PW. Liver fibrosis: A balance of ACEs? Clin Sci (Lond) 2007;113:109-18
94. Paizis G, Gilbert RE, Cooper ME, Murthi P, Schembri JM, Wu LL, et al. Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. J Hepatol 2001;35:376-85.
95. Cho JJ, Hocher B, Herbst H, Jia JD, Ruehl M, Hahn EG, et al. An oral endothelin: A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis. Gastroenterology 2000;118:1169-78.
96. Galli A, Crabb DW, Ceni E, Salzano R, Mello T, Svegliati-Baroni G, et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002;122:1924-40.
97. Marra F, Efsen E, Romanelli RG, Caligiuri A, Pastacaldi S, Batignani G, et al. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 2000;119:466-78.